PET/CT Characterization of Treatment Resistance
20
about 3 years
18+
Male only
1 site in WI
What this study is about
Researchers are testing different types of medical imaging to see how prostate cancer lesions become resistant to treatment. The trial is for men with advanced prostate cancer who are starting or already taking second-generation androgen receptor (AR) targeted therapy. Participants will be in it for at least 9 months, and up to 2 years.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.F-fluorodeoxyglucose positron emission tomography (FDG PET)
- 2.Prostate-specific membrane antigen positron emission tomography (PSMA PET)
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Secondary: Correlate amount of intrinsic resistance on FDG and PSMA PET to predict time to radiographic progression
imaging
Oncology